Alzheimer's Disease/Cognition News

For older adult males, negative changes in life space were associated with faster cognitive decline and increased risk for neurodegenerative disorders after 7 years, according to research from JAMA Network Open.

PHILADELPHIA — A 48-month intervention to lower BP in patients with uncontrolled hypertension also reduced risk for dementia and cognitive impairment, according to data presented at the American Heart Association Scientific Sessions.

RetinalGeniX Technologies announced that it submitted patent applications for investigational drug candidates RTG-2023 and RTG-2024, for age-related macular degeneration and Alzheimer’s, respectively.

Treatment with brexpiprazole 2 mg or 3 mg resulted in significant reduction in agitation over 12 weeks compared with placebo in adults with Alzheimer’s dementia, according to research published in JAMA Neurology.

The American Brain Foundation has announced the launch of a $10 million cross-disciplinary research initiative for neuroscientists to investigate the role of neuroinflammation in a wide range of neurologic and psychiatric brain diseases.

A Canadian neuroimaging company has received an investment from the Alzheimer’s Drug Discovery Foundation to accelerate development of novel biomarkers for Alzheimer’s disease and related dementias.

A systematic review and meta-analysis of trial literature found that medications investigated for treatment of agitation in dementia demonstrated no significant effect on cognition, according to a poster presentation at CTAD.

Annovis Bio has been permitted by the Data and Safety Monitoring Board to continue its phase 2/3 trial of buntanetap, an oral protein inhibitor for moderate to mild Alzheimer’s disease, according to a company release.

In a cohort of older adults, the COVID-19 pandemic was a mitigating factor in self-perceived cognitive decline, the presence of which indicated a higher risk factor for worsening cognitive function in the year following the pandemic.

For early detection of Alzheimer’s disease in older adults, comorbidities remained strongly associated with mild cognitive impairment, but prediction decreased with age, according to a poster presentation at CTAD.